{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:33:38Z","timestamp":1772764418828,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Odontology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiangiogenic medications target the de novo blood vessel formation in tumorigenesis. However, these novel drugs have been linked to the onset of medication-related osteonecrosis of the jaw (MRONJ). The aim of this in vitro study was to examine the effects of the vascular endothelial growth factor A (VEGFA) antibody bevacizumab (BEV) and the receptor tyrosine kinase inhibitor (RTKI) sunitinib (SUN) on primary human osteoblasts derived from the alveolar bone. Primary human alveolar osteoblasts (HAOBs) were treated with BEV or SUN for 48\u00a0h. Cellular metabolic activity was examined by XTT assay. Differentially regulated genes were identified by screening of 22 selected osteogenic and angiogenic markers by quantitative real-time reverse transcriptase polymerase chain reaction (qRT<jats:sup>2<\/jats:sup>-PCR). Protein levels of alkaline phosphatase (ALP), collagen type 1, \u03b11 (COL1A1) and secreted protein acidic and cysteine rich (SPARC) were examined by enzyme-linked immunoassay (ELISA). Treatment with BEV and SUN did not exhibit direct cytotoxic effects in HAOBs as confirmed by XTT assay. Of the 22 genes examined by qRT<jats:sup>2<\/jats:sup>-PCR, four genes were significantly regulated after BEV treatment and eight genes in the SUN group as compared to the control group. Gene expression levels of ALPL, COL1A1 and SPARC were significantly downregulated by both drugs. Further analysis by ELISA indicated the downregulation of protein levels of ALP, COL1A1 and SPARC in the BEV and SUN groups. The effects of BEV and SUN in HAOBs may be mediated by alterations to osteogenic and catabolic markers. Therapeutic or preventive strategies in MRONJ may address drug-induced depression of osteoblast differentiation.<\/jats:p>","DOI":"10.1007\/s10266-022-00691-y","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T11:02:56Z","timestamp":1645009376000},"page":"634-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-9278","authenticated-orcid":false,"given":"Elena","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz-Josef","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Nokhbehsaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"691_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/ijms21020455","volume":"21","author":"A Mukherjee","year":"2020","unstructured":"Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent advancements of nanomedicine towards antiangiogenic therapy in cancer. Int J Mol Sci. 2020;21:455. https:\/\/doi.org\/10.3390\/ijms21020455.","journal-title":"Int J Mol Sci"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107\u201313. https:\/\/doi.org\/10.1634\/theoncologist.12-1-107.","journal-title":"Oncologist"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40259-020-00449-4","volume":"34","author":"LC Brown","year":"2020","unstructured":"Brown LC, Desai K, Zhang T, Ornstein MC. The immunotherapy landscape in renal cell carcinoma. BioDrugs. 2020;34:733\u201348. https:\/\/doi.org\/10.1007\/s40259-020-00449-4.","journal-title":"BioDrugs"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","volume":"12","author":"MH Cohen","year":"2007","unstructured":"Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12:356\u201361. https:\/\/doi.org\/10.1634\/theoncologist.12-3-356.","journal-title":"Oncologist"},{"key":"691_CR5","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.4317\/medoral.23191","volume":"25","author":"A Eguia","year":"2020","unstructured":"Eguia A, Bag\u00e1n-Deb\u00f3n L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020;25:e71\u201383. https:\/\/doi.org\/10.4317\/medoral.23191.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"691_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel R, Tr\u00f6ltzsch M, K\u00fchnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44:568\u201385. https:\/\/doi.org\/10.1016\/j.ijom.2015.01.026.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"691_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567\u201375. https:\/\/doi.org\/10.1016\/j.joms.2005.07.010.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","volume":"35","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw\u20142009 update. Aust Endod J. 2009;35:119\u201330. https:\/\/doi.org\/10.1111\/j.1747-4477.2009.00213.x.","journal-title":"Aust Endod J"},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jop.13083","volume":"50","author":"V Moraschini","year":"2021","unstructured":"Moraschini V, Calasans-Maia MD, Louro RS, Arantes EBR, Calasans-Maia JdA. Weak evidence for the management of medication-related osteonecrosis of the jaw: an overview of systematic reviews and meta-analyses. J Oral Pathol Med. 2021;50:10\u201321. https:\/\/doi.org\/10.1111\/jop.13083.","journal-title":"J Oral Pathol Med"},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115\u20137. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, S\u00e1ndor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405.","journal-title":"J Bone Miner Res"},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181\u20138. https:\/\/doi.org\/10.1007\/s10549-010-0866-3.","journal-title":"Breast Cancer Res Treat"},{"key":"691_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","volume":"24","author":"SB Wedam","year":"2006","unstructured":"Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769\u201377. https:\/\/doi.org\/10.1200\/JCO.2005.03.4645.","journal-title":"J Clin Oncol"},{"key":"691_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/labinvest.2011.162","volume":"92","author":"O Attar-Schneider","year":"2012","unstructured":"Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest. 2012;92:178\u201390. https:\/\/doi.org\/10.1038\/labinvest.2011.162.","journal-title":"Lab Invest"},{"key":"691_CR16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQM Chow","year":"2007","unstructured":"Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884\u201396. https:\/\/doi.org\/10.1200\/JCO.2006.06.3602.","journal-title":"J Clin Oncol"},{"key":"691_CR17","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327\u201337.","journal-title":"Clin Cancer Res"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","volume":"16","author":"J Chang","year":"2018","unstructured":"Chang J, Hakam AE, McCauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep. 2018;16:584\u201395. https:\/\/doi.org\/10.1007\/s11914-018-0474-4.","journal-title":"Curr Osteoporos Rep"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/jop.12205","volume":"44","author":"P Lopez Jornet","year":"2015","unstructured":"Lopez Jornet P, Susana SC, Rosario TM, Alvaro P-F. Zoledronic acid and irradiation in oral squamous cell carcinoma. J Oral Pathol Med. 2015;44:103\u20138. https:\/\/doi.org\/10.1111\/jop.12205.","journal-title":"J Oral Pathol Med"},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1600-0714.2012.01154.x","volume":"41","author":"S Patntirapong","year":"2012","unstructured":"Patntirapong S, Singhatanadgit W, Chanruangvanit C, Lavanrattanakul K, Satravaha Y. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition. J Oral Pathol Med. 2012;41:713\u201320. https:\/\/doi.org\/10.1111\/j.1600-0714.2012.01154.x.","journal-title":"J Oral Pathol Med"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/odi.12761","volume":"24","author":"SO Akintoye","year":"2018","unstructured":"Akintoye SO. The distinctive jaw and alveolar bone regeneration. Oral Dis. 2018;24:49\u201351. https:\/\/doi.org\/10.1111\/odi.12761.","journal-title":"Oral Dis"},{"key":"691_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00784-014-1354-7","volume":"19","author":"F Wehrhan","year":"2015","unstructured":"Wehrhan F, Amann K, M\u00f6bius P, Weber M, Preidl R, Ries J, Stockmann P. BRONJ-related jaw bone is associated with increased Dlx-5 and suppressed osteopontin\u2014implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates. Clin Oral Investig. 2015;19:1289\u201398.","journal-title":"Clin Oral Investig"},{"key":"691_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49:42\u20139. https:\/\/doi.org\/10.1016\/j.bone.2011.01.014.","journal-title":"Bone"},{"key":"691_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/jop.12281","volume":"44","author":"J Su","year":"2015","unstructured":"Su J, Feng M, Han W, Zhao H. The effects of bisphosphonate on the remodeling of different irregular bones in mice. J Oral Pathol Med. 2015;44:638\u201348.","journal-title":"J Oral Pathol Med"},{"key":"691_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.bone.2005.10.027","volume":"38","author":"SO Akintoye","year":"2006","unstructured":"Akintoye SO, Lam T, Shi S, Brahim J, Collins MT, Robey PG. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone. 2006;38:758\u201368. https:\/\/doi.org\/10.1016\/j.bone.2005.10.027.","journal-title":"Bone"},{"issue":"9","key":"691_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1359\/jbmr.060614","volume":"21","author":"V Everts","year":"2006","unstructured":"Everts V, Korper W, Hoeben KA, Jansen IDC, Bromme D, Cleutjens M, Kitty BJM, Heeneman S, Peters C, Reinheckel T, Saftig P, Beertsen W. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res. 2006;21(9):1399\u2013408. https:\/\/doi.org\/10.1359\/jbmr.060614.","journal-title":"J Bone Miner Res"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.joms.2011.05.002","volume":"70","author":"D Marolt","year":"2012","unstructured":"Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R. Effects of pamidronate on human alveolar osteoblasts in vitro. J Oral Maxillofac Surg. 2012;70:1081\u201392. https:\/\/doi.org\/10.1016\/j.joms.2011.05.002.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR28","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00784-014-1353-8","volume":"19","author":"J-T Lee","year":"2015","unstructured":"Lee J-T, Choi S-Y, Kim H-L, Kim J-Y, Lee H-J, Kwon T-G. Comparison of gene expression between mandibular and iliac bone-derived cells. Clin Oral Investig. 2015;19:1223\u201333. https:\/\/doi.org\/10.1007\/s00784-014-1353-8.","journal-title":"Clin Oral Investig"},{"key":"691_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1601-0825.2007.01402.x","volume":"14","author":"D Stefanik","year":"2008","unstructured":"Stefanik D, Sarin J, Lam T, Levin L, Leboy PS, Akintoye SO. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis. 2008;14:465\u201371. https:\/\/doi.org\/10.1111\/j.1601-0825.2007.01402.x.","journal-title":"Oral Dis"},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"X Gong","year":"2017","unstructured":"Gong X, Yu W, Zhao H, Su J, Sheng Q. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity. Sci Rep. 2017;7:1\u201313.","journal-title":"Sci Rep"},{"key":"691_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oooo.2016.08.009","volume":"123","author":"SS Lim","year":"2017","unstructured":"Lim SS, Lee B, Kim IS, Hwang SJ. Differential modulation of zoledronate and etidronate in osseous healing of an extracted socket and tibia defect. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:8\u201319.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"691_CR32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00784-015-1706-y","volume":"20","author":"S Zafar","year":"2016","unstructured":"Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ. Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts. Clin Oral Investig. 2016;20:2023\u201335. https:\/\/doi.org\/10.1007\/s00784-015-1706-y.","journal-title":"Clin Oral Investig"},{"issue":"3","key":"691_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/adj.12752","volume":"65","author":"KI McLaughlin","year":"2020","unstructured":"McLaughlin KI, Milne TJ, Zafar S, Zanicotti DG, Cullinan MP, Seymour GJ, Coates DE. The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation. Aust Dent J. 2020;65(3):196\u2013204. https:\/\/doi.org\/10.1111\/adj.12752.","journal-title":"Aust Dent J"},{"key":"691_CR34","doi-asserted-by":"publisher","first-page":"E0179248","DOI":"10.1371\/journal.pone.0179248","volume":"12","author":"S Gao","year":"2017","unstructured":"Gao S, Zheng G, Wang L, Liang Y, Zhang S, Lao X, Li K, Liao G. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS ONE. 2017;12:E0179248.","journal-title":"PLoS ONE"},{"key":"691_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs AJ, Jauhiainen M, M\u00f6nkk\u00f6nen H, Rogers MJ, M\u00f6nkk\u00f6nen J, Thompson K. Peripheral blood monocytes are responsible for \u03b3\u03b4 T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br J Haematol. 2009;144:245\u201350. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07435.x.","journal-title":"Br J Haematol"},{"key":"691_CR36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","volume":"66","author":"R Landesberg","year":"2008","unstructured":"Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839\u201347. https:\/\/doi.org\/10.1016\/j.joms.2008.01.026.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","volume":"45","author":"P Lesclous","year":"2009","unstructured":"Lesclous P, Abi Najm S, Carrel J-P, Baroukh B, Lombardi T, Willi J-P, Rizzoli R, Saffar J-L, Samson J. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009;45:843\u201352. https:\/\/doi.org\/10.1016\/j.bone.2009.07.011.","journal-title":"Bone"},{"key":"691_CR38","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26:4037\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.15.5424.","journal-title":"J Clin Oncol"},{"key":"691_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"67","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67:61\u201370. https:\/\/doi.org\/10.1016\/j.joms.2009.01.007.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092969","volume":"9","author":"D Marolt","year":"2014","unstructured":"Marolt D, Rode M, Kregar-Velikonja N, Jeras M, Knezevic M. Primary human alveolar bone cells isolated from tissue samples acquired at periodontal surgeries exhibit sustained proliferation and retain osteogenic phenotype during in vitro expansion. PLoS ONE. 2014;9: e92965. https:\/\/doi.org\/10.1371\/journal.pone.0092969.","journal-title":"PLoS ONE"},{"key":"691_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1755-3768.2008.01257.x","volume":"87","author":"A Carneiro","year":"2009","unstructured":"Carneiro A, Falc\u00e3o M, Azevedo I, Falc\u00e3o Reis F, Soares R. Multiple effects of bevacizumab in angiogenesis: implications for its use in age-related macular degeneration. Acta Ophthalmol. 2009;87:517\u201323. https:\/\/doi.org\/10.1111\/j.1755-3768.2008.01257.x.","journal-title":"Acta Ophthalmol"},{"key":"691_CR42","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1593\/neo.11948","volume":"14","author":"U Adamcic","year":"2012","unstructured":"Adamcic U, Skowronski K, Peters C, Morrison J, Coomber BL. The effect of bevacizumab on human malignant melanoma cells with functional VEGF\/VEGFR2 autocrine and intracrine signaling loops. Neoplasia. 2012;14:612\u201323. https:\/\/doi.org\/10.1593\/neo.11948.","journal-title":"Neoplasia"},{"key":"691_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3892\/br.2017.961","volume":"7","author":"H Lee","year":"2017","unstructured":"Lee H, Park J-B. Evaluation of the effects of dimethylsulphoxide on morphology, cellular viability, mRNA, and protein expression of stem cells culture in growth media. Biomed Rep. 2017;7:291\u20136. https:\/\/doi.org\/10.3892\/br.2017.961.","journal-title":"Biomed Rep"},{"key":"691_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.pmbts.2017.05.001","volume":"148","author":"KBS Paiva","year":"2017","unstructured":"Paiva KBS, Granjeiro JM. Matrix metalloproteinases in bone resorption, remodeling, and repair. Prog Mol Biol Transl Sci. 2017;148:203\u2013303. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.05.001.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"691_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0092-8674(01)00622-5","volume":"108","author":"K Nakashima","year":"2002","unstructured":"Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17\u201329. https:\/\/doi.org\/10.1016\/s0092-8674(01)00622-5.","journal-title":"Cell"},{"key":"691_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jcp.2007.048868","volume":"61","author":"HK Datta","year":"2008","unstructured":"Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol. 2008;61:577\u201387. https:\/\/doi.org\/10.1136\/jcp.2007.048868.","journal-title":"J Clin Pathol"},{"key":"691_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1359\/jbmr.2000.15.4.663","volume":"15","author":"E Abe","year":"2000","unstructured":"Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O\u2019Brien CA, Economides AN, Stahl N, Jilka RL, Manolagas SC. Essential requirement of BMPs-2\/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res. 2000;15:663\u201373.","journal-title":"J Bone Miner Res"},{"key":"691_CR48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1021\/pr050420t","volume":"5","author":"CS Alge","year":"2006","unstructured":"Alge CS, Hauck SM, Priglinger SG, Kampik A, Ueffing M. Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cytoskeletal remodeling and cell survival. J Proteome Res. 2006;5:862\u201378. https:\/\/doi.org\/10.1021\/pr050420t.","journal-title":"J Proteome Res"},{"key":"691_CR49","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2147\/OTT.S65055","volume":"7","author":"K-A Norton","year":"2014","unstructured":"Norton K-A, Han Z, Popel AS, Pandey NB. Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells. Onco Targets Ther. 2014;7:1571\u201382. https:\/\/doi.org\/10.2147\/OTT.S65055.","journal-title":"Onco Targets Ther"},{"key":"691_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000321905","volume":"86","author":"PA Videira","year":"2011","unstructured":"Videira PA, Piteira AR, Cabral MG, Martins C, Correia M, Severino P, Gouveia H, Carrascal M, Almeida JF, Trindade H, Santos LL. Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. Urol Int. 2011;86:95\u2013101. https:\/\/doi.org\/10.1159\/000321905.","journal-title":"Urol Int"},{"key":"691_CR51","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","volume":"60","author":"L Segerstr\u00f6m","year":"2006","unstructured":"Segerstr\u00f6m L, Fuchs D, B\u00e4ckman U, Holmquist K, Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res. 2006;60:576\u201381. https:\/\/doi.org\/10.1203\/01.pdr.0000242494.94000.52.","journal-title":"Pediatr Res"},{"key":"691_CR52","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1158\/0008-5472.CAN-09-3722","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Li Y, Luo W-M, Zhang Z-F, Snider J, Vandenbeldt K, Qian C-N, Teh BT. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010;70:1053\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3722.","journal-title":"Cancer Res"},{"key":"691_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fbioe.2017.00068","volume":"5","author":"A Grosso","year":"2017","unstructured":"Grosso A, Burger MG, Lunger A, Schaefer DJ, Banfi A, Di Maggio N. It takes two to tango: coupling of angiogenesis and osteogenesis for bone regeneration. Front Bioeng Biotechnol. 2017;5:68. https:\/\/doi.org\/10.3389\/fbioe.2017.00068.","journal-title":"Front Bioeng Biotechnol"},{"key":"691_CR54","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","volume":"65","author":"EP Wang","year":"2007","unstructured":"Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328\u201331. https:\/\/doi.org\/10.1016\/j.joms.2007.03.006.","journal-title":"J Oral Maxillofac Surg"},{"key":"691_CR55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471\u201394. https:\/\/doi.org\/10.1007\/s10456-014-9420-y.","journal-title":"Angiogenesis"},{"key":"691_CR56","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3892\/ol.2019.10518","volume":"18","author":"LM Kroschwald","year":"2019","unstructured":"Kroschwald LM, Tauer JT, Kroschwald SI, Suttorp M, Wiedenfeld A, Beissert S, Bauer A, Rauner M. Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro. Oncol Lett. 2019;18:2102\u20138. https:\/\/doi.org\/10.3892\/ol.2019.10518.","journal-title":"Oncol Lett"},{"key":"691_CR57","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1600-0714.2012.01173.x","volume":"41","author":"S Saracino","year":"2012","unstructured":"Saracino S, Canuto RA, Maggiora M, Oraldi M, Scoletta M, Ciuffreda L, Vandone AM, Carossa S, Mozzati M, Muzio G. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model. J Oral Pathol Med. 2012;41:788\u201392. https:\/\/doi.org\/10.1111\/j.1600-0714.2012.01173.x.","journal-title":"J Oral Pathol Med"},{"key":"691_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1083\/jcb.200201089","volume":"157","author":"M Kato","year":"2002","unstructured":"Kato M, Patel MS, Levasseur R, Lobov I, Chang BH-J, Glass DA, Hartmann C, Li L, Hwang T-H, Brayton CF, Lang RA, Karsenty G, Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157:303\u201314. https:\/\/doi.org\/10.1083\/jcb.200201089.","journal-title":"J Cell Biol"},{"key":"691_CR59","doi-asserted-by":"publisher","first-page":"14817","DOI":"10.1038\/s41598-020-71749-6","volume":"10","author":"S Morkmued","year":"2020","unstructured":"Morkmued S, Clauss F, Schuhbaur B, Fraulob V, Mathieu E, Hemmerl\u00e9 J, Clevers H, Koo B-K, Doll\u00e9 P, Bloch-Zupan A, Niederreither K. Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent bone loss. Sci Rep. 2020;10:14817. https:\/\/doi.org\/10.1038\/s41598-020-71749-6.","journal-title":"Sci Rep"},{"key":"691_CR60","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/er.2004-0001","volume":"26","author":"K Janssens","year":"2005","unstructured":"Janssens K, ten Dijke P, Janssens S, van Hul W. Transforming growth factor-\u03b21 to the bone. Endocr Rev. 2005;26:743\u201374. https:\/\/doi.org\/10.1210\/er.2004-0001.","journal-title":"Endocr Rev"},{"key":"691_CR61","doi-asserted-by":"publisher","first-page":"C853","DOI":"10.1152\/ajpcell.2000.278.4.C853","volume":"278","author":"DS Steinbrech","year":"2000","unstructured":"Steinbrech DS, Mehrara BJ, Saadeh PB, Greenwald JA, Spector JA, Gittes GK, Longaker MT. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. Am J Physiol Cell Physiol. 2000;278:C853\u201360. https:\/\/doi.org\/10.1152\/ajpcell.2000.278.4.C853.","journal-title":"Am J Physiol Cell Physiol"},{"key":"691_CR62","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/mmr.2020.10965","volume":"21","author":"A Ding","year":"2020","unstructured":"Ding A, Bian Y-Y, Zhang Z-H. SP1\/TGF-\u03b21\/SMAD2 pathway is involved in angiogenesis during osteogenesis. Mol Med Rep. 2020;21:1581\u20139. https:\/\/doi.org\/10.3892\/mmr.2020.10965.","journal-title":"Mol Med Rep"},{"key":"691_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115305","volume":"135","author":"S Pal","year":"2020","unstructured":"Pal S, Rashid M, Singh SK, Porwal K, Singh P, Mohamed R, Gayen JR, Wahajuddin M, Chattopadhyay N. Skeletal restoration by phosphodiesterase 5 inhibitors in osteopenic mice: evidence of osteoanabolic and osteoangiogenic effects of the drugs. Bone. 2020;135: 115305. https:\/\/doi.org\/10.1016\/j.bone.2020.115305.","journal-title":"Bone"},{"key":"691_CR64","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s12017-014-8324-8","volume":"16","author":"T Simon","year":"2014","unstructured":"Simon T, Coquerel B, Petit A, Kassim Y, Demange E, Le Cerf D, Perrot V, Vannier J-P. Direct effect of bevacizumab on glioblastoma cell lines in vitro. Neuromol Med. 2014;16:752\u201371. https:\/\/doi.org\/10.1007\/s12017-014-8324-8.","journal-title":"Neuromol Med"},{"key":"691_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3892\/mmr_00000271","volume":"3","author":"DL Basi","year":"2010","unstructured":"Basi DL, Lee SW, Helfman S, Mariash A, Lunos SA. Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells. Mol Med Rep. 2010;3:399\u2013403. https:\/\/doi.org\/10.3892\/mmr_00000271.","journal-title":"Mol Med Rep"},{"key":"691_CR66","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jop.12021","volume":"42","author":"J Bagan","year":"2013","unstructured":"Bagan J, Sheth CC, Soria JM, Margaix M, Bagan L. Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. J Oral Pathol Med. 2013;42:405\u20138. https:\/\/doi.org\/10.1111\/jop.12021.","journal-title":"J Oral Pathol Med"},{"key":"691_CR67","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jop.12640","volume":"46","author":"PG de Barros Silva","year":"2017","unstructured":"de Barros Silva PG, Ferreira Junior AEC, de Oliveira CC, Brizeno LAC, Wong DVT, Lima J\u00fanior RCP, Sousa FB, Mota MRL, Alves APNN. Chronic treatment with zoledronic acid increases inflammatory markers in periodontium of rats. J Oral Pathol Med. 2017;46:1046\u201353. https:\/\/doi.org\/10.1111\/jop.12640.","journal-title":"J Oral Pathol Med"},{"key":"691_CR68","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4110\/in.2018.18.e8","volume":"18","author":"DS Amarasekara","year":"2018","unstructured":"Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J. Regulation of osteoclast differentiation by cytokine networks. Immune Netw. 2018;18:e8\u2013e8. https:\/\/doi.org\/10.4110\/in.2018.18.e8.","journal-title":"Immune Netw"},{"key":"691_CR69","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/endo.141.11.7739","volume":"141","author":"L Gilbert","year":"2000","unstructured":"Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, Nanes MS. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956\u201364. https:\/\/doi.org\/10.1210\/endo.141.11.7739.","journal-title":"Endocrinology"},{"key":"691_CR70","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jnci\/djq516","volume":"103","author":"M Pazianas","year":"2011","unstructured":"Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011;103:232\u201340. https:\/\/doi.org\/10.1093\/jnci\/djq516.","journal-title":"J Natl Cancer Inst"},{"key":"691_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","volume":"335","author":"SE Aldridge","year":"2005","unstructured":"Aldridge SE, Lennard TWJ, Williams JR, Birch MA. Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun. 2005;335:793\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2005.07.145.","journal-title":"Biochem Biophys Res Commun"},{"key":"691_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00784-014-1219-0","volume":"19","author":"N Hagelauer","year":"2015","unstructured":"Hagelauer N, Pabst AM, Ziebart T, Ulbrich H, Walter C. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Investig. 2015;19:139\u201348. https:\/\/doi.org\/10.1007\/s00784-014-1219-0.","journal-title":"Clin Oral Investig"},{"key":"691_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","volume":"170","author":"SL Teitelbaum","year":"2007","unstructured":"Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170:427\u201335. https:\/\/doi.org\/10.2353\/ajpath.2007.060834.","journal-title":"Am J Pathol"},{"key":"691_CR74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q","volume":"192","author":"TJ Chambers","year":"2000","unstructured":"Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol. 2000;192:4\u201313.","journal-title":"J Pathol"},{"key":"691_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131041","volume":"10","author":"JL Pathak","year":"2015","unstructured":"Pathak JL, Bakker AD, Verschueren P, Lems WF, Luyten FP, Klein-Nulend J, Bravenboer N. CXCL8 and CCL20 enhance osteoclastogenesis via modulation of cytokine production by human primary osteoblasts. PLoS ONE. 2015;10: e0131041. https:\/\/doi.org\/10.1371\/journal.pone.0131041.","journal-title":"PLoS ONE"},{"key":"691_CR76","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/ar.20737","volume":"291","author":"G Sipos","year":"2008","unstructured":"Sipos G, Sipos P, Altdorfer K, Pongor \u00c9, Feh\u00e9r E. Correlation and immunolocalization of substance P nerve fibers and activated immune cells in human chronic gastritis. Anat Rec. 2008;291:1140\u20138. https:\/\/doi.org\/10.1002\/ar.20737.","journal-title":"Anat Rec"},{"key":"691_CR77","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.2527\/jas.2007-0462","volume":"86","author":"M Lorenzo","year":"2008","unstructured":"Lorenzo M, Fern\u00e1ndez-Veledo S, Vila-Bedmar R, Garcia-Guerra L, de Alvaro C, Nieto-Vazquez I. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci. 2008;86:E94\u2013104. https:\/\/doi.org\/10.2527\/jas.2007-0462.","journal-title":"J Anim Sci"},{"key":"691_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/edrv.23.1.0456","volume":"23","author":"J Pfeilschifter","year":"2002","unstructured":"Pfeilschifter J, K\u00f6ditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90\u2013119. https:\/\/doi.org\/10.1210\/edrv.23.1.0456.","journal-title":"Endocr Rev"},{"key":"691_CR79","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1600-0714.2009.00878.x","volume":"39","author":"M Biasotto","year":"2010","unstructured":"Biasotto M, Chiandussi S, Zacchigna S, Moimas S, Dore F, Pozzato G, Cavalli F, Zanconati F, Contardo L, Giacca M, Di Lenarda R. A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. J Oral Pathol Med. 2010;39:390\u20136. https:\/\/doi.org\/10.1111\/j.1600-0714.2009.00878.x.","journal-title":"J Oral Pathol Med"}],"container-title":["Odontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10266-022-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10266-022-00691-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10266-022-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:10:39Z","timestamp":1662703839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10266-022-00691-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s10266-022-00691-y","relation":{},"ISSN":["1618-1247","1618-1255"],"issn-type":[{"value":"1618-1247","type":"print"},{"value":"1618-1255","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and\/ or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of the Faculty of Medicine at the University of Bonn (Lfd. Nr. 086\/11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}